![71DMjDEL1ZL._CLa|1283,1076|81MfEDAtTAL.jpg,81z8cpPFE0L.jpg|0,0,583,1076+700,0,583,1076+291,0,700,1076_._SY200_.jpg 71DMjDEL1ZL._CLa|1283,1076|81MfEDAtTAL.jpg,81z8cpPFE0L.jpg|0,0,583,1076+700,0,583,1076+291,0,700,1076_._SY200_.jpg](https://m.media-amazon.com/images/I/71DMjDEL1ZL._CLa%7C1283,1076%7C81MfEDAtTAL.jpg,81z8cpPFE0L.jpg%7C0,0,583,1076+700,0,583,1076+291,0,700,1076_._SY200_.jpg)
71DMjDEL1ZL._CLa|1283,1076|81MfEDAtTAL.jpg,81z8cpPFE0L.jpg|0,0,583,1076+700,0,583,1076+291,0,700,1076_._SY200_.jpg
![Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications - ScienceDirect Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523423004130-ga1.jpg)
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications - ScienceDirect
Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry
![Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c00063/asset/images/medium/jm2c00063_0017.gif)
Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry
![Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein | Journal of Medicinal Chemistry Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.0c00471/asset/images/medium/jm0c00471_0016.gif)
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein | Journal of Medicinal Chemistry
![Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c00063/asset/images/large/jm2c00063_0008.jpeg)
Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer | Journal of Medicinal Chemistry
![Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications - ScienceDirect Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523423004130-gr1.jpg)